Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularizatio
Not Applicable
- Conditions
- Choroidal neovascularization associated with pathological myopia
- Registration Number
- JPRN-UMIN000008588
- Lead Sponsor
- Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) intraocular surgery of any kind within six months of the day of injection, 2) any other ocular disease that could compromise vision in the study eye, 3) ocular hypertension or glaucoma 4) uncontrolled systemic hypertension; peripheral vascular disease and history of thromboembolism, ischemic heart disease or stroke.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method